Method for analyzing related substances of a pharmaceutical composition containing a polymeric carrier
A method for analyzing related substances in a pharmaceutical composition containing an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block as a polymeric drug carrier, related substances identified thereby, and a method for evaluating a pharmaceutical composition by using the same are provided. Preferably, the method comprises evaluating a polymeric micelle pharmaceutical composition, which comprises an amphiphilic block copolymer comprising a hydrophilic block (A) and a hydrophobic block (B), and paclitaxel or docetaxel as a poorly water-soluble drug, by using a compound represented by Chemical Formula 1, wherein the hydrophilic block (A) comprises one or more selected from the group consisting of polyethylene glycol or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof; and the hydrophobic block (B) is polylactide.
1. A method for evaluating a polymeric micelle pharmaceutical composition, comprising evaluating a polymeric micelle pharmaceutical composition, which comprises an amphiphilic block copolymer comprising a hydrophilic block (A) and a hydrophobic block (B), and paclitaxel or docetaxel as a poorly water-soluble drug, by using a compound represented by the following Formula 1 as a standard material;
wherein the hydrophilic block (A) comprises one or more selected from the group consisting of polyethylene glycol or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof; and the hydrophobic block (B) is polylactide:
wherein
R 1 is H or C(O)CH 3 , and R 2 is phenyl or OC(CH 3 ) 3 .
2. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 1 , wherein the poorly water-soluble drug is paclitaxel, the compound represented by Formula 1 is a compound represented by the following Formula 1c:
3. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is recognized as satisfying a quality standard if it contains, when stored at 40° C. for 6 months, the compound represented by Formula 1 in an amount of 0.8 part by weight or less, based on 100 parts by weight of an initial amount of the poorly water-soluble drug.
4. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 1 , wherein the compound of Formula 1 includes a compound of the following Formula 1a, a compound of the following Formula 1b, or both a compound of Formula 1a and a compound of Formula 1b:
5. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 4 , wherein the pharmaceutical composition is recognized as satisfying a quality standard if it contains the compound of Formula 1a in an amount of 0.3 part by weight or less, based on 100 parts by weight of an initial amount of the poorly water-soluble drug, and the compound of Formula 1b in an amount of 0.5 part by weight or less, based on 100 parts by weight of an initial amount of the poorly water-soluble drug.
6. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 1 , wherein the polymeric micelle pharmaceutical composition is evaluated by analyzing the compound represented by Formula 1 by steps comprising:
(1) preparing a sample for analysis of the polymeric micelle pharmaceutical composition; and
(2) analyzing related substances in the prepared sample by high performance liquid chromatography (HPLC) using the following conditions (a) and (b):
(a) a stationary phase of porous particles having a particle size of 4 μm or less; and
(b) a column having an inner diameter of 5 mm or less and a length of 50 mm or more.
7. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , wherein the stationary phase of porous particles is a pentafluorophenyl stationary phase.
8. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , wherein the high performance liquid chromatography is carried out by using a stationary phase of porous particles having a particle size of 1.5 to 4 μm and a column having an inner diameter of 2 to 5 mm and a length of 50 to 250 mm.
9. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , further comprising qualitatively analyzing the related substances, which are isolated in step (2) by liquid chromatography/mass spectrometry (LC/MS), liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), nuclear magnetic resonance (NMR) or a combination thereof.
10. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 9 , wherein the LC/MS or LC/MS/MS is carried out by using (c) a hybrid octadecyl-silica (ODS) stationary phase; and (d) a column having an inner diameter of 10 mm or less and a length of 500 mm or less.
11. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , wherein an ultraviolet (UV) detector is used to detect the related substances.
12. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , wherein the hydrophilic block (A) is polyethylene glycol or monomethoxypolyethylene glycol.
13. The method for evaluating a polymeric micelle pharmaceutical composition according to claim 6 , wherein the hydrophilic block (A) has a number average molecular weight of 200 to 20,000 Daltons; and the hydrophobic block (B) has a number average molecular weight of 200 to 20,000 Daltons.